Skip to main content
    P

    Phathom Pharmaceuticals Inc (PHAT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.50
    -0.38 (-6.46%)

    Market Cap: $477.99M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Phathom Pharmaceuticals Inc (PHAT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Phathom Pharmaceuticals (PHAT) has a market cap of $477.99M and an enterprise value of $458.98M. Revenue grew 86.75% over the last 12 months from the 12 months before. Its share count is up 15.66% from a year earlier.

    Total Valuation

    Enterprise value is 3.98% below the market cap, as cash exceeds debt.

    Market Cap$477.99M
    Enterprise Value$458.98M
    Latest price (Nov 17, 2026)$5.50

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.37% in the quarter ended Sep 30, 2026 and grew 14.61% a year over 2 years.

    Shares Outstanding84.89M
    Shares Change (YoY)+15.66%
    Shares Change (QoQ)+1.37%
    Share Count Growth (2Y CAGR)+14.61%

    Valuation Ratios

    The price to sales ratio is 1.7x. Its year-end P/S ranged from 6.9x to 686.6x from 2023 to 2025.

    P/S Ratio1.7x
    Forward P/S1.5x

    Price Statistics

    The stock is down 62.23% over 52 weeks and trades 19.35% below its 50-day average.

    Beta (1Y)0.97
    52-Week Change-62.23%
    1-Month Change-21.54%
    3-Month Change-40.99%
    6-Month Change-51.75%
    5-Year Change-75.61%
    Total Return (1Y)-62.23%
    Total Return (3Y CAGR)-9.82%
    Total Return (5Y CAGR)-23.41%
    Return vs SPY (1Y)-74.89%
    Max Drawdown (1Y)-71.90%
    Max Drawdown (3Y)-88.26%
    Sharpe Ratio (1Y)-1.41
    Correlation with SPY (1Y)0.19
    50-Day Average$6.82
    200-Day Average$9.95
    52-Week Range$5.01 to $18.31
    RSI (14 Days)39.6
    Average Volume (20 Days)1.89M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.76x current liabilities.

    Current Ratio1.76x
    Quick Ratio1.72x
    Interest Coverage-0.42x

    Returns and Efficiency

    Return on invested capital is 11.43% over the last 12 months, against a 5-year average of 55.24%.

    Return on Assets (ROA)-24.06%
    Return on Invested Capital (ROIC)11.43%
    Return on Capital Employed (ROCE)-15.48%
    ROA (5Y Average)-83.68%
    ROIC (5Y Average)55.24%
    Asset Turnover0.94x
    Inventory Turnover6.92x
    Receivables Turnover2.68x
    Cash Conversion Cycle132 days

    Scores

    PHAT has an Altman Z-Score of -4.86, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-4.86
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $274.88M over the last 12 months.

    Revenue$274.88M
    Revenue Growth (YoY)+86.75%
    Gross Profit$221.78M
    Operating Income-$25.45M
    Pretax Income-$83.00M
    Net Income-$83.00M
    EBITDA-$22.35M
    EBIT-$26.34M
    Reported EPS (TTM)-$0.45

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$184.56M
    Total Debt$165.54M
    Net Cash$19.02M
    Net Cash Per Share$0.22
    Working Capital$133.11M
    Shareholder Equity-$347.64M
    Total Assets$345.02M
    Total Liabilities$692.66M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $302.00K of capital spending, operating cash flow left -$21.04M of free cash flow.

    Operating Cash Flow-$20.74M
    Capital Expenditures$302.00K
    Free Cash Flow-$21.04M
    FCF Per Share-$0.26
    Depreciation and Amortization$3.99M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -9.26%.

    Gross Margin80.68%
    Operating Margin-9.26%
    Pretax Margin-30.19%
    Net Margin-30.19%
    EBITDA Margin-8.13%
    EBIT Margin-9.58%
    FCF Margin-7.65%

    Dividends and Yields

    PHAT does not pay a dividend. Its free cash flow yield is -4.51%.

    FCF Yield-4.51%
    Shareholder Yield0.00%

    Peer Position

    Against 7 similar companies, PHAT has the 6th highest P/S.

    P/S Ratio1.7x vs 7.2x median
    ROIC11.43% vs -32.76% median
    Revenue Growth (Trailing 4 Quarters, YoY)+86.75% vs -69.50% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 66.94% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+66.94%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PHAT

    What is PHAT's market cap?

    Phathom Pharmaceuticals has a market cap of $477.99M. Its enterprise value, which adds debt and subtracts cash, is $458.98M.

    How many shares of PHAT are outstanding?

    Phathom Pharmaceuticals has 84.89M shares outstanding. The count is up 15.66% from a year earlier.

    Does PHAT pay a dividend?

    No. Phathom Pharmaceuticals does not pay a dividend.

    How much debt does PHAT have?

    Phathom Pharmaceuticals has $165.54M of total debt and $184.56M of cash and equivalents, a net cash position of $19.02M.